# Boston Scientific Corporation

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/boston-scientific-corporation/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | worldwide developer, manufacturer and marketer of medical devices |
| OpenAlex ID | https://openalex.org/F4320310567 |
| ROR ID | https://ror.org/0385es521 |
| Works | 13,455 |

## Funder papers

Showing 15 of 18.

- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-heart-failure-outcomes-after-acute-myocardial/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries](https://scholariq.org/papers/prevalence-and-outcomes-of-isolated-tricuspid-valve-surgery-among-medicare/)
- [Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)](https://scholariq.org/papers/double-blind-randomized-placebo-controlled-trial-evaluating-the-efficacy-and/)
- [Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial](https://scholariq.org/papers/virtual-house-calls-for-parkinson-disease-connect-parkinson-study-protocol-for-a/)
- [Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR-Preserved](https://scholariq.org/papers/early-changes-in-estimated-glomerular-filtration-rate-post-initiation-of-2/)
- [Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction](https://scholariq.org/papers/long-term-outcomes-with-cardiac-resynchronization-therapy-in-patients-with-mild/)
- [Predicting the need for step-up after EUS-guided drainage of peripancreatic fluid collections, including Quadrant-Necrosis-Infection score validation: a prospective cohort study](https://scholariq.org/papers/predicting-the-need-for-step-up-after-eus-guided-drainage-of-peripancreatic/)
- [Cost Analysis of Target Lesion Revascularisation in Patients With Femoropopliteal In Stent Re-Stenosis or Occlusion: The COSTLY-TLR Study](https://scholariq.org/papers/cost-analysis-of-target-lesion-revascularisation-in-patients-with/)
- [Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial](https://scholariq.org/papers/endoscopic-ultrasound-guided-choledochoduodenostomy-vs-endoscopic-retrograde/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.